Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
Annexon, Inc. (ANNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
08/08/2023 SC 13G/A FEDERATED HERMES, INC. reports a 4.4% stake in ANNEXON, INC.
08/07/2023 8-K Quarterly results
Docs: "ANNEXON, INC. Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 30,251 $ 29,106 $ 62,596 $ 56,104 General and administrative 7,440 8,303 16,337 16,731 Total operating expenses 37,691 37,409 78,933 72,835 Loss from operations Interest and other income, net 2,503 272 5,069 325 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share, basic and diluted 75,230,003 38,584,400 74,546,995 38,573,950 _______________________ Includes the following stock-based compensation expense: Research and development $ 2,307 $ 2,117 $ 4,558 $ 4,076 General and administrative $ 2,353 $ 2,403 $ 4,709 $ 4,696 ANNEXON, INC. Cond..."
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/31/2023 8-K Quarterly results
07/13/2023 144 Form 144 - Report of proposed sale of securities:
07/13/2023 144 Form 144 - Report of proposed sale of securities:
07/13/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/30/2023 SC 13G/A Bain Capital Life Sciences Fund, L.P. reports a 5.5% stake in Annexon, Inc.
05/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function"
05/08/2023 8-K Quarterly results
Docs: "ANNEXON, INC. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 32,345 $ 26,998 General and administrative 8,897 8,428 Total operating expenses 41,242 35,426 Loss from operations Interest and other income, net 2,566 53 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average shares used in computing net loss per share, basic and diluted 73,855,642 38,563,384 _______________________ Includes the following stock-based compensation expense: Research and development $ 2,251 $ 1,959 General and administrative $ 2,356 $ 2,293 ANNEXON, INC. Condensed Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 144,120 $ 140,020 Short-term investme..."
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ANNEXON, INC. Condensed Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 28,535 $ 27,217 $ 112,501 $ 100,066 General and administrative 8,160 10,241 33,098 30,647 Total operating expenses 36,695 37,458 145,599 130,713 Loss from operations Interest and other income , net 2,312 87 3,652 390 Net loss Net loss attributable to common stockholders $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 72,368,539 38,479,221 54,673,572 38,316,273 _______________________ Includes the following stock-based compensation expense: Research..."
03/06/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 SC 13G CITADEL ADVISORS LLC reports a 5.2% stake in Annexon, Inc.
02/14/2023 SC 13G/A Venrock Healthcare Capital Partners II, L.P. reports a 10% stake in Annexon, Inc.
02/14/2023 SC 13G/A Fairmount Funds Management LLC reports a 7.7% stake in ANNEXON, INC.
02/14/2023 SC 13G/A EVENTIDE ASSET MANAGEMENT, LLC reports a 7.6% stake in Annexon, Inc.
02/14/2023 SC 13G/A Bain Capital Life Sciences Fund, L.P. has filed a Schedule 13D for Annexon, Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/01/2023 SC 13G/A FEDERATED HERMES, INC. reports a 6.4% stake in ANNEXON, INC.
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Company Presentation, dated January 2023",
"Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises"
01/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio"
11/17/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/16/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/04/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy